Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
NCT07328737

One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei

Led by Beijing Tsinghua Chang Gung Hospital · Updated on 2026-01-09

132

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei (PMP). The main questions it aims to answer are: * Does receiving three HIPEC sessions lead to better Progression-Free Survival (PFS) and Overall Survival (OS) compared to one session? * What are the differences in postoperative complications (e.g., infection, bowel obstruction, myelosuppression) and organ toxicity (e.g., liver/kidney injury) between the two regimens? * How do the different treatment schedules impact patients' quality of life? Researchers will compare the experimental group (3 HIPEC sessions) to the control group (1 HIPEC session) to investigate the efficacy and safety of the additional sessions. Participants will: * Be randomly assigned to one of two groups: 1. Control Group: Receive only a single intraoperative HIPEC session following CRS. 2. Experimental Group: Receive two additional HIPEC sessions after CRS+HIPEC (on post-operative day 2 and day 4) at reduced drug doses. * Undergo scheduled safety checks for side effects on days 1, 3, 5, 7, and 10 post-HIPEC. * Attend a follow-up visit at 1 month after CRS+HIPEC and, if eligible, receive 6 cycles of standard postoperative chemotherapy. * Attend regular long-term follow-up visits for several years, which will include physical examinations, blood tests (for tumor markers), CT scans, and quality-of-life questionnaires (EORTC QLQ-C30 version 3.0).

CONDITIONS

Official Title

One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. Voluntarily consent to participate, sign informed consent, and be willing and able to comply with the study protocol;

  2. Age 18-70 years;

  3. Undergo CRS+HIPEC with pathological diagnosis of PMP of high grade with signet-ring cells, high grade, or low grade;

  4. Karnofsky performance status (KPS) >60;

  5. Adequate function of major organs as follows:

    1. Hematology: WBC ≥3.5×10^9/L, ANC ≥1.0×10^9/L, LC ≥0.5×10^9/L, PLT ≥80×10^9/L, Hb ≥90 g/L;
    2. Hepatic function: AST, ALT, and TBIL ≤2×upper limit of normal (ULN);
    3. Renal function: serum creatinine <1.2×ULN;
    4. Coagulation: APTT ≤1.5×ULN; INR or PT ≤1.5×ULN;
    5. Cardiopulmonary function sufficient to tolerate major surgery and HIPEC;

(5) Radiological Peritoneal Cancer Index (PCI) ≥15; (6) No local or systemic antitumor therapy within 1 month prior to CRS+HIPEC; (7) Adverse reactions from prior treatments have resolved before study initiation or, in the investigator's judgment, will not interfere with this study;

Not Eligible

You will not qualify if you...

  1. Metastases to lung, brain, bone, or liver;
  2. AST, ALT, or TBIL ≥2×ULN;
  3. Serum creatinine ≥1.2×ULN;
  4. Severe mesenteric contraction;
  5. Major organ dysfunction that cannot support the planned procedures;
  6. Concomitant hematological disorders or other malignancies;
  7. Acute or subacute infectious disease;
  8. History of allergy to cisplatin or docetaxel, or marked allergic diathesis or severe allergy history;
  9. Psychiatric or psychological disorders preventing cooperation with treatment and efficacy evaluation;
  10. Any other condition deemed unsuitable for enrollment by the investigator;

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tsinghua University affiliated Beijing Tsinghua Changgung Hospital

Beijing, Changping, China, 102218

Actively Recruiting

Loading map...

Research Team

R

Rui Yang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei | DecenTrialz